$ALT

Altimmune, Inc. (ALT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated

Altimmune Inc. (ALT) announced the addition of Peter Greenleaf and Alex Howarth to its board, effective November 2. Three current board members will retire. Greenleaf has leadership experience at Aurinia and Sucampo, while Howarth previously served as CFO at Madrigal. Altimmune is developing pemvidutide for MASH, AUD, and ALD, with FDA designations and ongoing trials.

Altimmune (ALT) will present new data on pemvidutide at AASLD 2026, including 48-week Phase 2b results and preclinical findings. The data shows reductions in fibrosis markers, improved GI tolerability, and reduced alcohol intake in a hamster model. The update reinforces earlier Phase 2b signals and advances the drug into Phase 3 trials.

Altimmune, Inc. (ALT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 24, 2026, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) appointed Richard Menziuso a

Novo Nordisk (NVO) announced plans for larger acquisitions and over five multi-blockbuster launches by 2030, targeting $23B in pipeline sales by 2035. Shares of smaller obesity-focused companies Viking Therapeutics (VKTX), Structure Therapeutics (GPCR), and Altimmune (ALT) rose, while NVO shares fell 8%. NVO's CagriSema treatment showed promising weight loss results, but investors remain cautious.

Altimmune (ALT) shares rose 14.2% since its last earnings report, outperforming the S&P 500. The company reported a narrower Q2 2026 loss of 12 cents per share, beating estimates, but no revenue. R&D expenses increased 8.2% YoY, and cash reserves grew to $519M. Analysts revised estimates upward by 11.29%. The stock has a Zacks Rank #3 (Hold).

Altimmune (ALT) reported Q2 results, highlighting progress in three liver disease trials. The company launched a global Phase 3 trial for MASH, reported positive Phase 2 data for alcohol use disorder, and completed enrollment for a Phase 2 trial in alcohol-associated liver disease. Altimmune has no approved products and reported a net loss of $22.8 million, with cash reserves of $519 million as of June 30.

Altimmune has begun a Phase 3 trial for pemvidutide, a dual-hormone drug targeting metabolic dysfunction-associated steatohepatitis (MASH). The drug uniquely balances glucagon and GLP-1 receptor activation, aiming to address liver fat and fibrosis. The trial's success could validate its differentiation in a crowded market. Altimmune's valuation is highly dependent on the outcome, with a price-to-sales ratio of 72.5x.

$ALT stock rose 7% today with $4.17M in trading volume. Insiders made 6 purchases in the last 6 months. 142 institutional investors increased their positions in Q2 2026. Analysts set price targets ranging from $10 to $20.

Lululemon (LULU), Lucid (LCID), and Altimmune (ALT) hit 52-week lows due to leadership uncertainty, financial strain, and strategic concerns. LULU dropped 13% after naming a new CEO, LCID fell 9% amid funding and production cost worries, and ALT declined 16% following a stock offering. Uber owns 11.52% of LCID.